Abbonarsi

Hair analysis for the detection and quantification of letrozole after single and repeated use - 27/04/19

Doi : 10.1016/j.toxac.2019.03.084 
D. Favretto 1, 2, G. Pelletti 3, , R. Snenghi 1, R. Pertile 1, R. El Mazloum 2, M. Tucci 2, S. Visentin 1, 2, S. Vogliardi 2
1 University Hospital of Padova, Padova, Italy 
2 Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padova, Padova, Italy 
3 Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Objective

Letrozole is an aromatase inhibitor, used to treat post-menopausal women with hormone receptor-positive or advanced breast cancer. It is prohibited in sport because it is used together with androgen anabolizing steroids to avoid their adverse effects. In case of adverse analytical finding, it may be important to distinguish between repetitive use due to voluntary administration and occasional use, possibly due to involuntary intake. With the objective to identify the dose capable of producing a positive hair testing, this study aims at investigating the incorporation into hair of single or repeated doses of letrozole.

Methods

Four subjects were recruited to investigate the incorporation in hair after ingestion of letrozole. Hair samples were obtained from: (i) 2 subjects (A and B) in chronic therapy with 2.5mg of letrozole/day and (ii) 2 subjects (C and D) who ingested one dosage of 2.5mg and 0.62mg of letrozole, respectively. From subject A and B a whole length hair sample was collected, and segmental analysis was performed on 1cm long segments. From subjects C and D, beard hair was sampled by shaving before administration (t=0), 3 days after administration, and 6 days after administration. Head hairs were cut close to the scalp 10 and 90 days after administration. Analysis were performed through HPLC–HRMS.

Results

Letrozole was present in concentration higher than 160pg/mg in all segments from subjects A and B. In subject C a detectable amount of the analyte in beard of the first 3 days (160pg/mg in 0–3 days), up to the 6th day (130pg/mg in 3–6 days) after ingestion and in head hair collected 10 days after ingestion (60pg/mg) were found. In subject D, a lower amount of letrozole both in beard (100 and 85pg/mg) and in head hair (30pg/mg) was determined. Letrozole was detected also in head hair collected 90 days after the drug administration (30pg/mg in C and 17pg/mg in subject D).

Conclusion

This preliminary study shows that a single administration of a therapeutic dose (2.5mg) or less than a dose (0.62mg) of the drug produces a positive hair sample. Moreover, the results highlight large differences between concentrations in hair of subjects who consumed a single dose and hair of subjects in chronic therapy and suggest a positive correlation between frequency and/or dose ingested and hair concentration. The relatively higher amount identified in beard when compared to head hair suggests a mixed mode of incorporation in beard through sweat and blood.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2019  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 31 - N° 2S

P. S57-S58 - maggio 2019 Ritorno al numero
Articolo precedente Articolo precedente
  • Les intoxications volontaires en milieu pédiatrique : expérience du service de toxicologie CHU Hassan II de Fès
  • H. Hoummani, M. Yacoubi-Sahli, M. Hida, S. Achour
| Articolo seguente Articolo seguente
  • Un stimulant sexuel pas si « naturel » que ça
  • M. Palayer, X. Duval, S. Ferec, C. Abbara, B. Lelièvre, G. Drevin, G. Le Roux, P. Compagnon

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.